Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing this prospect. This Special Issue will focus on state-of-the-art concepts in the evaluation and management of dyslipidemia, including the rationale for newly set goals in the lipid treatment of this disease given the recent ...
Read More
Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing this prospect. This Special Issue will focus on state-of-the-art concepts in the evaluation and management of dyslipidemia, including the rationale for newly set goals in the lipid treatment of this disease given the recent international guidelines, global trends in the epidemiology of dyslipidemia, the latest concepts and therapies in the evaluation and management of familial hypercholesterolemia, novel therapies for lowering LDL-C beyond statin therapy, the status of lipoprotein(a) as a causal risk factor and newer therapeutic approaches to address it, the evaluation and management of dyslipidemia in children, current and emerging therapies for hypertriglyceridemia, and nutraceuticals to treat dyslipidemia in patients with COVID-19. This Special Issue will discuss state-of-the-art clinical trials and other research developments regarding newer and emerging therapies for the management of dyslipidemia to reduce the residual risks of ASCVD. The hope is to provide clinicians with the latest information on the key aspects of the evaluation and treatment of dyslipidemia, including newer non-statin approaches for decreasing the residual risks of ASCVD, such as the settings of elevated LDL-C, lipoprotein(a), and familial hypercholesterolemia.
Read Less
Add this copy of New Advances in Dyslipidemia to cart. $63.96, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2024 by Mdpi AG.
Add this copy of New Advances in Dyslipidemia to cart. $101.70, new condition, Sold by GreatBookPrices rated 4.0 out of 5 stars, ships from Columbia, MD, UNITED STATES, published 2024 by Mdpi AG.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Sewn binding. Cloth over boards. 214 p. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Add this copy of New Advances in Dyslipidemia to cart. $101.71, new condition, Sold by Booksplease rated 3.0 out of 5 stars, ships from Southport, MERSEYSIDE, UNITED KINGDOM, published 2024 by Mdpi AG.
Add this copy of New Advances in Dyslipidemia to cart. $112.74, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2024 by Mdpi AG.
Add this copy of New Advances in Dyslipidemia to cart. $155.65, new condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2024 by Mdpi AG.
